Patients should stop using glucagon-like peptide-1 (GLP-1) agonists two weeks prior to a total joint arthroplasty to reduce the risk for anesthesia complications, according to new research presented at the 2025 annual meeting of the American Academy of Orthopaedic Surgeons.
A team of researchers examined how the timing of a patient’s last dose of the treatment before total hip (THA) or total knee arthroplasty (TKA) can influence complications related to anesthesia, including delayed